| PPP1R3D |
Homo sapiens |
|
PPP1R3D is differentially expressed in 103 experiments [102 up/113 dn]: 24 organism parts: peripheral blood [2 up/0 dn], white blood cells [0 up/1 dn], ...; 28 disease states: normal [3 up/6 dn], Huntington's disease [2 up/0 dn], ...; 19 cell types, 28 cell lines, 28 compound treatments and 21 other conditions. |
| PPP1R3D, PPP1R6 |
|
CC8.2 (Caenorhabditis elegans)
LOC682185 (Rattus norvegicus)
CG9619 (Drosophila melanogaster)
Ppp1r3d (Mus musculus)
zgc:174896 (Danio rerio)
(Compare orthologs)
|
|
|
| Protein phosphatase 1, glycogen targeting subunit, Metazoa, Putative phosphatase regulatory subunit |
|
|
| glycogen metabolic process, protein binding, protein serine/threonine phosphatase activity |
|
|
|
O95685
Q86X09
|
|
|
|
ENSG00000132825
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Normal
|
Disease state |
|
|
None
|
Compound treatment |
|
|
FLAP
|
Compound treatment |
|
|
MK886
|
Compound treatment |
|
|
MCF-7
|
Cell line |
|
|
BT-474
|
Cell line |
|
|
Fibroblast
|
Cell type |
|
|
Peripheral blood
|
Organism part |
|
|
Huntington's disease
|
Disease state |
|
|
HNRPA2B
|
Compound treatment |
|
|
SW480
|
Cell line |
|
|
SW620
|
Cell line |
|
|
Primary
|
Disease staging |
|
|
Male
|
Sex |
|
|
MCF7
|
Cell line |
|
|
Bacterial endotoxin
|
Compound treatment |
|
|
Control
|
Compound treatment |
|
|
Breast carcinoma
|
Disease state |
|
|
Glucocorticoid resistant
|
Phenotype |
|
|
White blood cells
|
Organism part |
|
|
SKMEL5
|
Cell line |
|
|
CodeLink Labeling
|
Protocol type |
|
|
Not applicable
|
Histology |
|
|
N/a
|
Test result |
|
|
Acute promyelocytic leukemia
|
Disease state |
|
|
U937
|
Cell line |
|
|
Invasive ductal carcinoma
|
Histology |
|
|
Pretreatment primary sample
|
Clinical info |
|
|
SsMCF7
|
Cell line |
|
|
PC3
|
Cell line |
|
|
0 cm away from the tumor bound...
|
Observation |
|
|
Stage II
|
Disease staging |
|
|
HPL1
|
Cell line |
|
|
Fu97
|
Cell line |
|
|
ERalpha transfected
|
Genotype |
|
|
ERbeta transfected
|
Genotype |
|
|
Mannitol
|
Compound treatment |
|
|
Affymetrix Labeling
|
Protocol type |
|
|
Methotrexate
|
Compound treatment |
|
|
AZ521
|
Cell line |
|
|
Cerebellum
|
Organism part |
|
|
Tumor
|
Organism part |
|
|
MDA-MB-231
|
Cell line |
|
|
In vitro neutrophil
|
Cell type |
|
|
Hypericin incubated, not irrad...
|
Growth condition |
|
|
Hypericin incubated, irradiate...
|
Growth condition |
|
|
Superficial transitional cell ...
|
Disease state |
|
|
Alveolar space neutrophil
|
Cell type |
|
|
Vanadium pentoxide
|
Compound treatment |
|
|
Lipopolysaccharide
|
Compound treatment |
|
|
Iloprost
|
Compound treatment |
|
|
SKBR3
|
Cell line |
|
|
Childhood acute myeloid leukem...
|
Disease state |
|
|
Glucocorticoid sensitive
|
Phenotype |
|
|
Trichostatin A
|
Compound treatment |
|
|
Poorly differentiated gastric ...
|
Disease state |
|
|
Endothelial cell
|
Cell type |
|
|
Enzo Labeling
|
Protocol type |
|
|
Potassium dichromate
|
Compound treatment |
|
|
MDA468
|
Cell line |
|
|
Epidermal growth factor
|
Compound treatment |
|
|
Rapamycin
|
Compound treatment |
|
|
Gastric cancer
|
Disease state |
|
|
Organism_part
|
Material type |
|
|
Cell
|
Material type |
|
|
Epilepsy
|
Disease state |
|
|
Atrial mycocardium
|
Organism part |
|
|
Ventricular myocardium
|
Organism part |
|
|
Superior cervical ganglion
|
Organism part |
|
|
Smooth muscle
|
Organism part |
|
|
Training set
|
Population |
|
|
Test set
|
Population |
|
|
X-linked chronic granulomatous
|
Disease state |
|
|
T47-D
|
Cell line |
|
|
Lymphoid tissue
|
Organism part |
|
|
Bone marrow
|
Organism part |
|
|
5-aza-2'-deoxycytidine
|
Compound treatment |
|
|
Sevoflurane
|
Compound treatment |
|
|
T-cell lymphoblastic lymphoma
|
Disease state |
|
|
Kaposi's sarcoma
|
Disease state |
|
|
Placebo
|
Compound treatment |
|
|
Glutamine
|
Compound treatment |
|
|
Johnsen score count 2: Sertoli...
|
Histology |
|
|
Trigeminal ganglion
|
Organism part |
|
|
Teratozoospermia
|
Disease state |
|
|
Normospermic
|
Disease state |
|
|
Oligodendroglioma
|
Disease state |
|
|
Control
|
Clinical info |
|
|
Hydrogen peroxide
|
Compound treatment |
|
|
T84
|
Cell line |
|
|
Caco-2
|
Cell line |
|
|
Synovial fluid
|
Organism part |
|
|
Monocyte at intermediate diffe...
|
Cell type |
|
|
M1 macrophage
|
Cell type |
|
|
Chronic lymphocytic leukemia
|
Disease state |
|
|
DMSO
|
Vehicle |
|
|
HeLa
|
Cell line |
|
|
18/22
|
Genotype |
|
|
T4aN0M0
|
Disease staging |
|
|
IgV status unknown
|
Genotype |
|
|
Endometrioid carcinoma
|
Disease state |
|
|
SkinEthic keratinocyte
|
Cell type |
|
|
Epidermal keratinocyte
|
Cell type |
|
|
Psoriatic lesional biopsy
|
Clinical info |
|
|
Uninvolved biopsy
|
Clinical info |
|
|
Idiopathic dilated cardiomyopa...
|
Disease state |
|
|
Heregulin
|
Compound treatment |
|
|
Unknown_sex
|
Sex |
|
|
MKN74
|
Cell line |
|
|
Epithelial cell
|
Cell type |
|
|
Stromal cell
|
Cell type |
|
|
Term
|
Developmental stage |
|
|
Midgestation
|
Developmental stage |
|
|
Ethanol
|
Vehicle |
|
|
T47D
|
Cell line |
|
|
Liver
|
Organism part |
|
|
Benign nevi
|
Disease state |
|
|
Interferon-gamma + lipopolysac...
|
Compound treatment |
|
|
Cigarette smoke
|
Growth condition |
|
|
Incubator control
|
Growth condition |
|
|
Cancer6
|
Replicate |
|
|
Grade IV
|
Tumor grading |
|
|
Granulocyte-colony stimulating...
|
Compound treatment |
|
|
Stage I
|
Disease staging |
|
|
Glioblastoma
|
Disease state |
|
|
Frontal cortex, primary motor ...
|
Organism part |
|
|
CD34+
|
Cell type |
|
|
Lymph node metastasis
|
Disease staging |
|
|
Cigarette smoke
|
Compound treatment |
|
|
CD71+ early erythroid
|
Cell type |
|
|
Stage IV/2
|
Disease staging |
|
|
Tissue culture polystyrene dis...
|
Growth condition |
|
|
Collagen/chondroitin tissue en...
|
Growth condition |
|
|
HTERT/HPVE6/HPVE7/SV40t transf...
|
Gene modification |
|
|
Dimethyl sulfoxide
|
Compound treatment |
|
|
17-allylamino-geldanamycin
|
Compound treatment |
|
|
Down syndrome
|
Disease state |
|
|
MCF10A
|
Cell line |
|
|
ITM-ST
|
Cell line |
|
|
Hematopoietic stem cell
|
Cell type |
|
|
Adipose tissue-derived stem ce...
|
Cell type |
|
|
Mesenchymal stem cell
|
Cell type |
|
|
HMEC184
|
Cell line |
|
|
Fetal thyroid
|
Organism part |
|
|
Multiple myeloma
|
Disease state |
|
|
Lymph node
|
Organism part |
|
|
Tonsil
|
Organism part |
|
|
None
|
Infection |
|
|
Carcinoma in situ lesion
|
Disease state |
|
|
Wild_type
|
Genotype |
|
|
PML/RAR
|
Genotype |
|
|
A549
|
Cell line |
|
|
Clear cell sarcoma of the kidn...
|
Disease state |
|
|
Kidney
|
Organism part |
|
|
Monocyte
|
Cell type |
|
|
Beta cell islets
|
Organism part |
|
|
Cystic change
|
Histology |
|
|
ITV
|
Cell line |
|
|
Carboplatin resistant
|
Test result |
|
|
Carboplatin sensitive
|
Test result |
|
|
Heat-killed HL60 cell lysate
|
Infection |
|
|
Homo sapiens
|
Organism |
|
|
Pan troglodytes
|
Organism |
|
|
Diagnosed with skin cancer bef...
|
Clinical history |
|
|
Ulcerative colitis
|
Disease state |
|
|
Skeletal muscle
|
Organism part |
|
|
None
|
Gene modification |
|
|
Estrogen receptor 1 positive; ...
|
Test result |
|
|
Baseline sevoflurane
|
Compound treatment |
|
|
T1bN0M0
|
Disease staging |
|
|
Cervical cancer
|
Disease state |
|
|
Ovary
|
Organism part |
|
|
IgV unmutated
|
Genotype |
|
|
Well-functioning transplant
|
Clinical info |
|
|
Uterine cervix
|
Organism part |
|
|
Prostate
|
Organism part |
|
|
BCKN-1
|
Cell line |
|
|
M-CSF
|
Compound treatment |
|
|
Small cell lung carcinoma
|
Disease state |
|
|
Endothelial cell + pericyte
|
Cell type |
|
|
Johnsen score count 10: full s...
|
Histology |
|
|
Female
|
Sex |
|
|
LEDGF knockdown
|
RNAi |
|
|
Control
|
RNAi |
|
|
Keratinocyte
|
Cell type |
|
|
Limited radiation toxicity
|
Clinical history |
|
|
Muscle invasive carcinoma
|
Disease state |
|
|
CD3+ CD4+ CD8- CD45RA+ CD62L+
|
Phenotype |
|
|
Naive T cell
|
Cell type |
|
|
Pancreas
|
Organism part |
|
|
YCC16
|
Cell line |
|
|
|
|
|
Processing time: 0.131 secs.